Richard E. Ringel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richard E. Ringel has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Kimberlee Gauvreau
Department of Cardiology (K.G.), Boston Children’s Hospital, MA
3 shared publicationsHeidi Moses
Department of Cardiology Boston Children's Hospital Boston MA
2 shared publicationsKathy J. Jenkins
Department of Cardiology Boston Children's Hospital Boston MA
2 shared publications- Alfredo Trento
Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
1 shared publication - Carl L. Tommaso
Division of Cardiology, NorthShore University HealthSystem, Skokie Hospital, Skokie, Illinois 60076, USA
1 shared publication - Carlos Ruiz
Department of Statistics University Carlos III of Madrid Spain
1 shared publication
Latest Publications
- 1 June 2021
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 14 (6) , 582-589
Long-Term Outcomes of the Coarctation of the Aorta Stent Trials
Background: Long-term outcome data of stent-implantation for coarctation of the aorta are limited. We report up to 5 years of postimplant follow-up in patients enrolled into the COAST (Coarctation of the Aorta Stent Trial) and the COAST II trial (Covered Cheatham-Platinum Stents for Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta), evaluating the bare and Covered Cheatham-Platinum Stents for the treatment of coarctation of the aorta and associated aortic wall injury. Methods: Data was prospectively collected during the 2 multi-center studies, enrolling 248 patients (COAST: n=121, COAST II: n=127). Late follow-up data (48–60 month) was compared with immediate (1 month) and early (12 months) follow-up. Results: There was a notable decrease in the use of antihypertensive medication, from 53% at immediate, to 42% at early, and 29% at late follow-up. The cumulative incidence of stent fractures was 0% immediately, 2.9% at early, and 24.4% at late follow-up. Independent predictors for stent fractures at late follow-up were age <18 years, male sex, minimum stent diameter ≥12 mm, and use of bare metal stent. The cumulative incidence of reintervention was 1.6% at immediate, 5.1% at early, and 21.3% at late follow-up. Independent predictors for reinterventions at late follow-up were age <18 years, post implantation systolic arm-leg blood pressure gradient ≥10 mm Hg, minimum stent diameter at implantation <12 mm, and initial coarctation minimum diameter <6 mm. There were 13 patients with aortic aneurysms, with a cumulative incidence of 6.3% at late follow-up. Conclusions: Coarctation stenting is effective at maintaining obstruction relief up to 60 months postimplant with reduction in the number of patients requiring antihypertensive medication. However, an increase in-stent fractures and reinterventions were observed between medium and long-term follow-up. Covered stents appear to confer some protection from the development of stent fractures but do not provide complete protection from late aneurysm formation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT00552812 and NCT01278303.
- 1 June 2021
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 14 (6) , 582-589
Long-Term Outcomes of the Coarctation of the Aorta Stent Trials
Background: Long-term outcome data of stent-implantation for coarctation of the aorta are limited. We report up to 5 years of postimplant follow-up in patients enrolled into the COAST (Coarctation of the Aorta Stent Trial) and the COAST II trial (Covered Cheatham-Platinum Stents for Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta), evaluating the bare and Covered Cheatham-Platinum Stents for the treatment of coarctation of the aorta and associated aortic wall injury. Methods: Data was prospectively collected during the 2 multi-center studies, enrolling 248 patients (COAST: n=121, COAST II: n=127). Late follow-up data (48–60 month) was compared with immediate (1 month) and early (12 months) follow-up. Results: There was a notable decrease in the use of antihypertensive medication, from 53% at immediate, to 42% at early, and 29% at late follow-up. The cumulative incidence of stent fractures was 0% immediately, 2.9% at early, and 24.4% at late follow-up. Independent predictors for stent fractures at late follow-up were age <18 years, male sex, minimum stent diameter ≥12 mm, and use of bare metal stent. The cumulative incidence of reintervention was 1.6% at immediate, 5.1% at early, and 21.3% at late follow-up. Independent predictors for reinterventions at late follow-up were age <18 years, post implantation systolic arm-leg blood pressure gradient ≥10 mm Hg, minimum stent diameter at implantation <12 mm, and initial coarctation minimum diameter <6 mm. There were 13 patients with aortic aneurysms, with a cumulative incidence of 6.3% at late follow-up. Conclusions: Coarctation stenting is effective at maintaining obstruction relief up to 60 months postimplant with reduction in the number of patients requiring antihypertensive medication. However, an increase in-stent fractures and reinterventions were observed between medium and long-term follow-up. Covered stents appear to confer some protection from the development of stent fractures but do not provide complete protection from late aneurysm formation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT00552812 and NCT01278303.
- Open Access
- 5 June 2018
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 7 (11)
Mind the Brain: Stroke Risk in Young Adults With Coarctation of the Aorta
- 5 June 2018
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 7 (11)
Open AccessMind the Brain: Stroke Risk in Young Adults With Coarctation of the Aorta
- Open Access
- 24 March 2015
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 149 (5) , e71-e78
SCAI/AATS/ACC/STS operator and institutional requirements for transcatheter valve repair and replacement, part III
- 24 March 2015
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 149 (5) , e71-e78
Open AccessSCAI/AATS/ACC/STS operator and institutional requirements for transcatheter valve repair and replacement, part III
- 7 October 2014
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 85 (3) , 421-427
NuMED covered cheatham‐platinum stent™ for the treatment or prevention of right ventricular outflow tract conduit disruption during transcatheter pulmonary valve replacement
Objective: Retrospectively assess the frequency of right ventricular outflow tract (RVOT) conduit disruption during transcatheter pulmonary valve replacement (TPVR) and the effectiveness and safety of NuMED Covered Cheatham‐Platinum Stents™ (CCPS) for its prevention or treatment.Background: There have been no published reports to date describing the safety and effectiveness of covered stents to prevent or treat RVOT conduit disruption during TPVR.Methods: Data regarding 251 TPVR procedures performed at multiple US investigational sites were retrospectively reviewed to explore the incidence and potential predictors of conduit disruption. In addition, data on the use of 69 CCPS implanted in 50 patients during TPVR was reviewed.Results: The overall incidence of conduit disruption requiring intervention was 6%. The only predictor identified was a very elevated RVOT conduit systolic pressure gradient. A pre‐existing conduit tear was present in nine, while 31 developed tears after conduit dilation and three, after TPVR. The CCPS was used prophylactically in seven. Conduit tears were prevented or repaired in 49/50 patients. No CCPS‐related acute complications were reported. At 6‐month follow‐up, no patient had more than mild pulmonary regurgitation and the mean Doppler RVOT gradient (12.7 ± 5.8 mm Hg) comparing favorably with that reported in the Melody TPV® IDE trial (20.0 ± 8.6 mm Hg).Conclusion: CCPS implantation can successfully treat RVOT conduit disruption without negative impact on the TPV function. This retrospective analysis suggests high RVOT conduit systolic pressure gradient is a risk factor for conduit tears during TPVR.
- 7 October 2014
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 85 (3) , 421-427
NuMED covered cheatham‐platinum stent™ for the treatment or prevention of right ventricular outflow tract conduit disruption during transcatheter pulmonary valve replacement
Objective: Retrospectively assess the frequency of right ventricular outflow tract (RVOT) conduit disruption during transcatheter pulmonary valve replacement (TPVR) and the effectiveness and safety of NuMED Covered Cheatham‐Platinum Stents™ (CCPS) for its prevention or treatment.Background: There have been no published reports to date describing the safety and effectiveness of covered stents to prevent or treat RVOT conduit disruption during TPVR.Methods: Data regarding 251 TPVR procedures performed at multiple US investigational sites were retrospectively reviewed to explore the incidence and potential predictors of conduit disruption. In addition, data on the use of 69 CCPS implanted in 50 patients during TPVR was reviewed.Results: The overall incidence of conduit disruption requiring intervention was 6%. The only predictor identified was a very elevated RVOT conduit systolic pressure gradient. A pre‐existing conduit tear was present in nine, while 31 developed tears after conduit dilation and three, after TPVR. The CCPS was used prophylactically in seven. Conduit tears were prevented or repaired in 49/50 patients. No CCPS‐related acute complications were reported. At 6‐month follow‐up, no patient had more than mild pulmonary regurgitation and the mean Doppler RVOT gradient (12.7 ± 5.8 mm Hg) comparing favorably with that reported in the Melody TPV® IDE trial (20.0 ± 8.6 mm Hg).Conclusion: CCPS implantation can successfully treat RVOT conduit disruption without negative impact on the TPV function. This retrospective analysis suggests high RVOT conduit systolic pressure gradient is a risk factor for conduit tears during TPVR.
- 15 May 2013
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 82 (4) , 503-510
Acute outcome of stent therapy for coarctation of the aorta: Results of the coarctation of the aorta stent trial
Objectives: The coarctation of the aorta stent trial (COAST) is a pivotal trial of the NuMED Cheatham Platinum Stent® for treatment of coarctation of the aorta (CoA).Background: CoA is a congenital obstruction to flow through the aorta. Stents have been used since the 1990s to treat CoA; none have been approved by the Food and Drug Administration for this indication.Methods: In a prospective, multicenter study 105 patients received stents for treatment of CoA. Data was collected in the catheterization laboratory, on discharge and at 1‐month postprocedure.Results: Of 105 patients, 69% were male; 57% had native CoA. Noninvasive, baseline systolic blood pressure (SBP) showed upper extremity (UE) SBP to be 140 ± 16 mm Hg and UE to lower extremity (LE) SBP difference 29 ± 17 mm Hg. At catheterization, baseline ratio of minimum CoA diameter to diameter of descending aorta (CoA:DAo) was 0.46 ± 0.16. Implants (104/105) were successful with one stent migration. There were no deaths or serious complications. Paradoxical hypertension occurred in 6%. Four percent of patients experienced somewhat serious adverse events related to the procedure. All patients achieved relief of ascending aorta to Dao pressure gradient: mean = 2.0 ± 4.0 mm Hg (P < 0.001). The CoA:DAo increased to 0.84 ± 0.18. At 1‐month, UE SBP was 120 ± 12 mm Hg, UE to LE SBP difference = −1 ± 12 mm Hg. Ninety‐nine percent of patients had UE to LE SBP difference <20 mm Hg.Conclusions: Stenting of CoA, using the NuMED Cheatham Platinum Stent, is acutely safe and effective for treatment of CoA.
- 15 May 2013
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 82 (4) , 503-510
Acute outcome of stent therapy for coarctation of the aorta: Results of the coarctation of the aorta stent trial
Objectives: The coarctation of the aorta stent trial (COAST) is a pivotal trial of the NuMED Cheatham Platinum Stent® for treatment of coarctation of the aorta (CoA).Background: CoA is a congenital obstruction to flow through the aorta. Stents have been used since the 1990s to treat CoA; none have been approved by the Food and Drug Administration for this indication.Methods: In a prospective, multicenter study 105 patients received stents for treatment of CoA. Data was collected in the catheterization laboratory, on discharge and at 1‐month postprocedure.Results: Of 105 patients, 69% were male; 57% had native CoA. Noninvasive, baseline systolic blood pressure (SBP) showed upper extremity (UE) SBP to be 140 ± 16 mm Hg and UE to lower extremity (LE) SBP difference 29 ± 17 mm Hg. At catheterization, baseline ratio of minimum CoA diameter to diameter of descending aorta (CoA:DAo) was 0.46 ± 0.16. Implants (104/105) were successful with one stent migration. There were no deaths or serious complications. Paradoxical hypertension occurred in 6%. Four percent of patients experienced somewhat serious adverse events related to the procedure. All patients achieved relief of ascending aorta to Dao pressure gradient: mean = 2.0 ± 4.0 mm Hg (P < 0.001). The CoA:DAo increased to 0.84 ± 0.18. At 1‐month, UE SBP was 120 ± 12 mm Hg, UE to LE SBP difference = −1 ± 12 mm Hg. Ninety‐nine percent of patients had UE to LE SBP difference <20 mm Hg.Conclusions: Stenting of CoA, using the NuMED Cheatham Platinum Stent, is acutely safe and effective for treatment of CoA.
- 1 July 2012
- Published by Elsevier in American Heart Journal
- Vol. 164 (1) , 7-13
Coarctation of the Aorta Stent Trial (COAST): Study design and rationale
- 1 July 2012
- Published by Elsevier in American Heart Journal
- Vol. 164 (1) , 7-13
Coarctation of the Aorta Stent Trial (COAST): Study design and rationale
- 1 April 2003
- Published by Elsevier in The American Journal of Cardiology
- Vol. 91 (8) , 1031-1032
Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease
- 1 April 2003
- Published by Elsevier in The American Journal of Cardiology
- Vol. 91 (8) , 1031-1032
Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease